.webp)
Settlement with Genevant and Arbutus removes legal overhang, refocusing investor attention on Moderna’s cancer vaccine pipeline.
Shares of Moderna climbed 9% on Wednesday following the resolution of a long running legal dispute over the technology underpinning its COVID19 vaccine. The settlement removes a major overhang allowing the company to shift focus to its broader pipeline particularly its oncology programs.
Under the agreement Moderna will pay up to $2.25 billion to Genevant Sciences and Arbutus Biopharma resolving all U.S. and international claims alleging unauthorized use of lipid nanoparticle technology in its COVID19 vaccine. Analysts highlighted the settlement as a significant milestone for Moderna, which has seen its stock fall nearly 90% from 2021 highs amid declining COVID vaccine demand. “The company now has certainty and is well funded through multiple late stage oncology readouts expected in 2026 representing new long-term growth drivers,” said Myles Minter.
Citi analyst Geoffrey Meacham noted the payments were lower than some Wall Street expectations that had anticipated costs exceeding $3 billion. Despite this, some caution remains. Bernstein analyst Courtney Breen warned that if the contingent payment becomes due Moderna’s cash reserves could fall to $3.2 billion by 2026 down from projected levels of $4.5 billion to $5 billion for this year. Breen also pointed to uncertainty around Moderna’s ongoing lawsuit against Pfizer and BioNTech as well as management’s historic guidance as factors that could complicate the company’s financial position.
With the legal issues cleared analysts expect investor attention to return to Moderna’s experimental cancer vaccines potentially marking the start of a new growth phase beyond COVID19. The settlement provides a clearer path for the company to capitalize on its research pipeline while limiting future legal risks tied to its foundational nanoparticle technology.
.webp)
.webp)
